IFW

Dkt. 2609/60726-AZ/JPW/GJG/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Moses Rodriquez and Daren Ure

Serial No. : 10/776,442 Group Art Unit: 1614

Filing Date : February 10, 2004

For : TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES BY ANTIBODIES AGAINST GLATIRAMER ACETATE

1185 Avenue of the Americas
New York, NY 10036
December 1, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.97(b)(3)

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following publication which is listed again on the attached Form PTO-1449 **(Exhibit A)**.

1. U.S. Patent No. 3,849,550, issued November 19, 1974 (Teitelbaum, et al.);

2. U.S. Patent No. 3,991,210, issued November 9, 1976 (Shea);

3. U.S. Patent No. 4,339,431, issued July 13, 1982 (Gaffer);

4. U.S. Patent No. 5,204,099, issued April 20, 1993 (Barbier, et al.);

5. U.S. Patent No. 5,554,372, issued September 10, 1996 (Hunter, et al.);

6. U.S. Patent No. 5,583,031, issued December 10, 1996 (Stern);

7. U.S. Patent No. 5,623,052, issued April 22, 1997 (McLean, et al.);

8. U.S. Patent No. 5,627,206, issued May 6, 1997 (Hupe, et al);

9. U.S Patent No. 5,668,117, issued September 16, 1997 (Shapiro);

10. U.S. Patent No. 5, 719,296, issued February 17, 1998 (Acton, et al.);

11. U.S. Patent No. 5,734,023 issued March 31, 1998 (Bishwajit, et al.);

12. U.S. Patent No. 5,858,964, issued January 12, 1999 (Aharoni, et al.);

14. U.S. Patent No. 5,886,156, issued March 23, 1999 (McLean, et al.);

15. U.S. Patent No. 5,958,972, issued September 28, 1999 (Hupe, et al.);

16. U.S. Patent No. 6,214,791, issued April 10, 2001 (Arnon, et al.);

17. U.S. Patent No. 6,342,476, issued January 29, 2002 (Konfino, et al.);

18. U.S. Patent No. 6,362,161, issued March 26, 2002 (Konfino, et al.);

19. U.S. Patent Publication No. US-2001-0055568-A1, published December 27, 2001 (Gilbert, et al.);

20. U.S. Patent Publication No. US-2002-0037848-A1, published March 28, 2002 (Eisenbach-Schwartz, et al.);

21. U.S. Patent Publication No. US-2003-0004099-A1, published January 2, 2003 (Eisenbach-Schwartz, et al.);

22. U.S. Serial No. 09/359,099, filed July 12, 1999 (Strominger, et al.);

23. U.S. Serial No. 09/405,743, filed September 24, 1999 (Gad, et al.) now U.S. Patent No. 6,514,938 issued February 4, 2003;

24. U.S. Serial No. 09/487,793, filed January 20, 2000 (Eisenbach-Schwartz, et al.)

25. U.S. Serial No. 09/620,216, filed July 20, 2000 (Eisenbach-Schwartz, et al.);

26. U.S. Serial No. 09/765,301, filed January 22, 2001 (Eisenbach-Schwartz, et al.) and Applicants point out that this reference was published as U.S. Patent Publication No. US-2002-0037848-A1 (Item 20 above) is a counterpart of PCT International Publication No. WO 01/93893 (PCT/US01/02118)(Item 46 below);

27. U.S. Serial No. 09/765,644, filed January 22, 2001 (Eisenbach-Schwartz, et al.) Applicants point out that this reference was published as U.S. Patent Publication No. US-2003-0004099-A1 (Item 21 above) and is a counterpart of PCT International Publication No. WO 01/52878 (PCT/US01/02117)(Item 45 below);

28. U.S. Serial No. 09/768,872, filed January 23, 2001, (Aharoni, et al.) published as U.S. Patent Publication No. US-2002-0055466-A1, May 9, 2002;

29. U.S. Serial No. 09/816,989, filed March 23, 2001 (Gad, et al.) now U.S. Patent No. 6,800,287, issued October

5, 2004. Applicants point out that this reference is a counterpart of U.S. Serial No. 09/405,743 (Item 23 above);

30. U.S. Serial No. 09/875,429, filed June 5, 2001 (Yong, et al.) published as U.S. Patent Publication No. US-2002-0077278-A1, June 20, 2002;

31. PCT International Publication No. WO 88/10120 (PCT/US88/02139), published December 29, 1988 (Weiner, et al.);

32. PCT International Publication No. WO 92/02543 (PCT/EP91/01420), published February 20, 1992;

33. PCT International Publication No. WO 94/03484 (PCT/US93/06249) published February 17, 1994 (McLean, et al.). Applicants point out that this reference is a counterpart of U.S. Patent No. 5,623,052 and U.S. Patent No. 5,886,156;

34. PCT International Publication No. WO 94/26774 (PCT/US94/05632), published November 24, 1994 (Alexander, et al.);

35. PCT International Publication No. WO 95/31997 (PCT/US94/05697), published November 30, 1995 (Reid, et al.);

36. PCT International Publication No. WO 95/33475 (PCT/EP95/02125), published December 14, 1995 (Kott, et al.);

37. PCT International Publication No. WO 95/26980 (PCT/US95/04121), published October 12, 1995 (Hackett, et al.);

38. PCT International Publication No. WO 95/31990 (PCT/US95/06551), published November 30, 1995 (Konfino, et al.) Applicants point out that this reference is a counterpart of U.S. Patent No. 5,800,808 and U.S. Patent No. 6,342,476;

39. PCT International Publication No. WO 98/30227 (PCT/US98/00375), published July 16, 1998 (Arnon, et al.). Applicants point out that this reference is a counterpart of US Patent No. 6,214,791;

40. PCT International Publication No. WO 00/05249 (PCT/US99/16617), published February 3, 2000 (Strominger, et al.). Applicants point out that this reference is a counterpart of U.S. Serial No. 09/359,099;

41. PCT International Publication No. WO 00/18794 (PCT/US99/22402) published April 6, 2000 (Gad, et al.). Applicants point out that this reference is a counterpart of U.S. Serial No. 09/405,743 (Exhibit 18) and U.S. Serial No. 09/816,989;

42. PCT International Publication No. WO 00/20010 (PCT/US99/22836), published April 13, 2000 (Flechter, et al.);

43. PCT International Publication No. WO 00/27417 (PCT/US99/27107), published May 18, 2000 (Aharoni, et al.);

44. PCT International Publication No. WO 01/85797 (PCT/US00/14902), published November 15, 2001 (Rodriguez, et al.);

45. PCT International Publication No. WO 01/52878 (PCT/US01/02117), published July 26, 2001 (Eisenbach-Schwartz, et al.);

46. PCT International Publication No. WO 01/93893 (PCT/US01/02118), published December 13, 2001 (Eisenbach-Schwartz, et al.);

47. PCT International Publication No. WO 01/60392 (PCT/US01/05198), published August 23, 2001 (Gilbert, et al.). Applicants point out that this reference is a counterpart of US Patent Publication No. US-2001-0055568-A1;

48. PCT International Publication No. WO 01/93828 (PCT/US01/18248), published December 13, 2001 (Yong and Chabot). Applicants point out that this reference

is a counterpart of U.S. Serial No. 875,429;

49. PCT International Publication No. WO 01/97846 (PCT/US01/19649), published December 27, 2001 (Rodriguez and Ure). Applicants point out that this reference is a counterpart of the subject application;

50. European Patent Application No. 0 383 620 A2, published August 22, 1990 (Cook);

51. European Patent No. 0 359 783 B1, published November 29, 1995 (Weiner, et al.). Applicants point out that this reference is a counterpart of PCT International Application No. PCT/US88/02139 (WO 88/10120);

52. Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", J. Neurol. Sci., 1977, 31, 433-438;

53. Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", Eur. J. Immunol., 1993, 23, 17-25;

54. Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", Immunol. Letters, 1997, 58, 79-87;

55. Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", Ann. Neurol., 1979, 6, 469-473;

56. Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", Israel J. Med. Sci., 1972, 8, 1759-1760;

57. Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", Neurol., 1978, 28, 336 (Abstract);

58. Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in Progress in Multiple Sclerosis Research (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;

59. Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis (Academic Press, New York, 1980) 105-107;

60. Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", Immunological Rev., 1981, 55, 5-30;

61. Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250;

62. Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689;

63. Arnon, et al., "On the Existence of Suppressor Cells", Int. Arch. Allergy Immunol., 1993, 100, 2-7;

64. Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", Israel J. Med. Sci., 1993, 29, 175-181;

65. Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", Therapeutic Immunol., 1994, 1, 65-70;

66. Asakura and Rodriguez, "A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination", Multiple Sclerosis, 1998, 4: 217-221;

67. Asakura, et al., "Targeting of IgMκ Antibodies to Oligodendrocytes Promotes CNS Remyelination", J. Neurosci., 1998, 18(19): 7700-7708;

68. Babu, et al., "Reevaluation of Response Patterns of Nonresponder Mice to GlPhe Polymers", Immunogen., 1983, 18(1): 97-100 (Abstract);

69. Babu, et al., "Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", J. Immunogenet., 1984, 11(3-4): 251-254;

70. Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", Seminars in Neurol., June 1994, 14(2), 146-153;

71. Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", Neurol., 1988, 38(Suppl. 2), 69-71;

72. Baxevanis, et al., "Genetic Control of T-Cell Proliferative Responses to Poly ($Glu^{40}Ala^{60}$) and Poly ($Glu^{51}Lys^{34}Tyr^{15}$): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", Immunogenetics, 1980, 11: 617-628;

73. Bieber, et al., "Antibody-Mediated Remyelination: Relevance to Multiple Sclerosis", Multiple Sclerosis, 2000, 6: S1-S5;

74. Bieber, et al., "Humoral Autoimmunity as a Mediator of CNS Repair", Trends in Neurosci., 2001, 24(11): S39-S44;

75. Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Ann. Neurol., 1980, 8, 117 (Abstract);

76. Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Trans. Am. Neurol. Assoc., 1980, 105, 348-350;

77. Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", Ann. Neurol., 1982, 11, 317-319;

78. Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", Ann. N.Y. Acad. Sci. (USA), 1984, 366-372;

79. Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., Immunological and Clinical Aspects of Multiple Sclerosis (MTP Press, The Hague, 1984) 144-150;

80. Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", Neurol., 1985, 35 (Suppl. 1), 103 (Abstract);

81. Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", Adv. Ther. (USA), 1987, 4, 206 (Abstract);

82. Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 408-414;

83. Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", Neurol., 1988, 38(Suppl. 2), 66-69;

84. Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis, Roma (Italy), September 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232;

85. Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in Handbook of Multiple Sclerosis (S.D. Cook Marcel Rekker, ed., 1990) 469-480;

86. Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", Neurol., 1991, 41, 533-539;

87. Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in Treatment of Multiple Scleorsis: Trial Design, Results and Future Perspectives (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198;

88. Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", J. Neuropath. Exp. Neurol., 1983, 42, 356 (Abstract);

89. Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", Ann. N.Y. Acad. Sci. (USA), 1984, 436, 498-499;

90. Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", Neurol., 1985, 35, 1754-1759;

91. Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", Neurol., 1985, 35 (Suppl. 1), 170 (Abstract);

92. Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", Neurol., 1986, 36, 92-94;

93. Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", Neurol., 1991, 41, 1317-1319;

94. Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", Drug Therapy, 1990, 31-32, 37-39, 42-43;

95. Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991;

96. Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993;

97. Cohen, "Fundamental Immunology", Systemic Autoimmunity, 4th Ed., 1999, 1083;

98. Cotton, "Options for Multiple Sclerosis Therapy", J.A.M.A. Medical News & Perspectives, 1994, 272(18), 1393;

99. De Kruyff, et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", Eur. J. Immunol., 1987, 17 (8): 1115-1120 (Abstract);

100. Deeb, et al., "Comparision of Freund's and Ribi Adjuvants for Inducing Antibodies to the Synthetic Antigen (TG)-AL in Rabbits", J. Immunol. Methods, 1992, 152(1): 105-113 (Abstract);

101. Dorling, et al., "Prospects for Xenografting", Curr. Opinions Immunol., 1994, 6, 765-769;

102. Durelli, "Immunotherapeutics of Multiple Sclerosis", Instituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino, 467-475;

103. Falo, et al., "Analysis of Antigen Presentation by Metabolically Inactive Accessory Cells and Their Isolated Membranes", Proc. Natl. Acad. Sci. USA, 1985, 82(19): 6647-6651 (Abstract);

104. Ferrara, et al., "Graft-Versus-Host Disease", New Eng. J. Med., 1991, 324, 667-674;

105. Francis, "The Current Therapy of Multiple Sclerosis", J. Clin. Pharmacy and Therapeutics, 1993, 18, 77-84;

106. Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", Department of Chemical Immunology, The Weizmann Institute of Science, 1994;

107. Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, 1994;

108. Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Israeli Biochem. Soc., 1994, 21-22 (Abstract);

109. Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", Israeli Immunol. Soc., May 3-4, 1994 (Abstract);

110. Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", J. Neurochem., 1994, 63(Suppl. I), 561;

111. Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits theBinding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Neurochem Mtg., August 14-19, 1994;

112. Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236;

113. Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", J. Immunol., 1998, 160, 4386-4397;

114. Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit

Type II Collagen-reactive T Cell Clones", Proc. Natl. Acad. Sci., October 1998, 95, 12528-12531;

115. Fridkis-Hareli, et al., "Binding of Random Copolymers of Three Amino Acids to Class II MHC Molecules", Intl. Immunol., 1999, 11(5): 635-641;

116. Fridkis-Hareli, et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, Human Immunology, 2000, 61(7), 640-650 (Abstract);

117. Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", Int. Immunol., 1990, 2(8), 713-718;

118. Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", Current Opin. Immunol., 2000, 12 (6): 704-711;

119. Henry, "Special Delivery", Chem. and Eng. News, Sept. 18, 2000, 49-54;

120. Herzenberger, et al., "Lack of Immune Response Gene Control for Induction of Epitope-specific Suppression

by TGAL Antigen", Nature, 1982, 295: 329-331 (Abstract);

121. Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", Neurol., 1994, 7, 250-254;

122. Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in Congress for Advances in the Understanding and Treatment of Multiple Sclerosis, Boston (USA), Oct. 28-29, 1992;

123. Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", Ann. Neurol., 1994, 36(Suppl.), 115-117;

124. Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", Chemical Abstracts, 1996, 125, 291993b;

125. Ju, et al., "Idiotypic Analysis of Antibodies Against the Terpolymer L-glutamic Acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT Idiotype Following Immunization with Various Synthetic Polymers Containing Glutamic Acid and Tyrosine", Eur. J. Immunol., 1979, 9(7): 553-560 (Abstract);

126. Kay, et al., "The Mechanism of Action of FK 506", Transplantation Proceedings, 1990, 22(1, Suppl. 1), 96-99;

127. Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" J. Neurol. Sci., 1979, 42, 267-274;

128. Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", Int. Arch. Allergy Immunol., 1993, 102, 309-320;

129. Kepsutlu, et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3), 227-235 (Abstract);

130. Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", Israel Neurological Assoc., December 19-20, 1994, Herzliya (Israel), 17;

131. Kropshofer, et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH_2-Terminal Including Proline as a Stop Signal for Trimming", J. Immunol., 1993, 151: 4732-4742;

132. Lai, et al., "Complementation of Class II a Alleles in the Immune Response to (Glulystyr) Polymers", Exp. Clin. Immunogenet., 1986, 3(1): 38-48 (Abstract);

133. Lai, et al., "Monoclonal T Cell Responses to Two Epitopes on a Single Immunogen Controlled by Two Distinct Genes", J. Immunol., 1986, 136(10): 3799-3804 (Abstract);

134. Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", Israel J. Med. Sci., 1979, 15, 868-869 (Abstract);

135. Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", J. Immunol., 1979, 123, 2156-2160 (Abstract);

136. Lee, et al., "Peptide and Protein Drug Delivery" in Advances in Parenteral Sciences (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695;

137. Li, et al., "Glatiramer Acetate Blocks the Activation of THP-1 Cells by Interferon-γ", Eur. J. Pharmacol., 1998, 342: 303-310;

138. Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", J. Neurol. Sci., 1983, 62, 281-293;

139. Matsunaga, et al., "Complementation of Class II A Alleles in the Immune Response to (Glu-Lys-Tyr)

Polymers", Yokohama Med. Bull., 1988, 39(1-2): 9-19 (Abstract);

140. Maurer, et al., "Interpretations of Immune Responses of Mice to Poly(Glu60Lys40), its Modified Derivatives, and the Terpolymers Poly (Glu55Lys37Leu8) and Poly (Glu56Lys37Ser7)", Clin. Immunol. Immunopathol., 1980, 15(3): 344-356 (Abstract);

141. McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", J. Neurol. Sci., 1980, 46, 137-143;

142. McGavern, et al., "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis", The Neuroscientist, 1999, 5(1): 19-28;

143. Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", J. Neurol., 1991(Suppl. 1) (Abstract);

144. Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis - Two-year Follow-up", in 9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Florence (Italy), October-November, 1993, 48 (Abstract);

145. Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in Encycl. Molecular Bio. (Oxford Blackwell

Science Ltd, 1994) 602-606;

146. Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", Israel J. Med. Sci., 1992, 28, 486 (Abstract);

147. Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in The IBC Conference on Multiple Sclerosis, San Diego (USA), December 10, 1993 (Abstract);

148. Milo, et al., "Additive Effect of Copolymer-1 and Interferon-β on the Immune Response to Myelin Basic Protein", Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine, 1994, 22;

149. Milo, et al., "Copolymer-1 and Interferon-β Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", J. Neuroimmunol., 1994, 54, 183 (Abstract);

150. Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", Neurol., 1994, 44(Suppl. 2), A212;

151. Milo, et al., "Additive Effects of Copolymer-1 and Interferon β-1b on the Immune Response to Myelin Basic Protein", J. Neuroimmunol., 1995, 61, 185-193;

152. Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", Neurologic Clinics, 1990, 8(1), 119-141;

153. Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", Am. Family Physician, 1994, 50(4), 845-847;

154. O'Connor, et al., "Powders" in The Science and Practice of Pharmacy, Remington, 1995, 2, 1598-1614

155. Pender, et al. Int. Med. Journal, 2002, 32: 554-563;

156. Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659

157. Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann. Neurol., 1999, 46: 253-256;

158. Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84;

159. Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington, 1995, 2, 1380-1416;

160. Rodriguez, Neurological Therapeutics, 1998, 15(3): 245-250;

161. Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396;

162. Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract);

163. Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810;

164. Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract);

165. Schwartz, et al., "Gene Complementation in the T Lymphocyte Proliferative Response to Poly (Glu57Lys38Tyr5): Evidence for Effects of Polymer Handling and Gene Dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract);

166. Sela, et al., "Experimental Allergic Encephalomyelitis" in Menarini Series on Immunopathology, vol. 1, First Symposium of Organ Specific Autoimmunity", Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21;

167. Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", Makromol. Chem. Macromol. Symp., 1993, 70/71, 147-155;

168. Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5;

169. Sykes, "Immunobiology of Transplantation", Faseb J., 1996, 10, 721-730;

170. Tarcic, et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract);

171. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", Israel J. Med. Sci., 1971, 7, 630-631 (Abstract);

172. Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", Nature, 1972, 240, 564-566;

173. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", Clin. Immunol. Immunopath., 1974, 3, 256-262;

174. Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", Israel J. Med. Sci., 1974, 10(9), 1172-1173;

175. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", Israel J. Med. Sci., 1977, 13, 1038 (Abstract);

176. Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in Cell Biology and Immunology of Leukocyte Function (Academic Press, New York, 1979) 681-685;

177. Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer - Relevance to Multiple Sclerosis", in Humoral Immunity in Neurological Diseases (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613;

178. Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in Proc. 7th Eur. Immunol. Mtg., Jerusalem, September 8-13, 1985

(Abstract);

179. Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", Proc. Natl. Acad. Sci. USA, 1988, 85, 9724-9728;

180. Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" J. Israel Med. Assoc., 1989, CXVI(9), 453-456;

181. Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137-141;

182. Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", Neurol., 1994, 44(Suppl. 2), A358;

183. Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", Israel J. Med. Sci., 1997, 33, 280-284;

184. The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", Abstracts of Symposia and Free Communication, Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6;

185. Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", Immunol. Today, 1985, 6(4), 141;

186. Tisch, et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 437-438;

187. Trannoy, et al., "Epitope-specific Regulation of the T Cell Repertoire: Carrier Recognition in Association with I-E or I-A Does Not Influence the Restriction of Hapten-Specific T Cells", Eur. J. Immunol., 1985, 15(12): 1215-1221 (Abstract);

188. Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", Transplantation, 1991, 52, 15-20;

189. Van Noort, et al., International Review of Cytology, 1995, 178: 127-205;

190. Warrington, et al., "Human Monoclonal Antibodies Reactive to Oligodendrocytes Promote Remyelination in a Model of Multiple Sclerosis", Neurobiology, 2000, 97(12): 6820-6825;

191. Warrington, et al., "Immunoglobulin-Mediated CNS Repair", J. Allergy Clin. Immunol., 2001, S121-S125;

192. Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", Israel J. Med. Sci., 1972, 8, 656-657;

193. Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", Immunochem., 1976, 13, 333-337;

194. Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984, 933;

195. Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", Current Opinion in Neurol. and Neurosurgery, 1992, 5, 203-211;

196. Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" Neur. Neurochir. Pol., 1990, 24, 113;

197. Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444;

198. Zisman, et al., "Direct Binding of a Synthetic Multichain Polypeptide to Class II Major Histocompatibility Complex Molecules on Antigen-presenting Cells and Stimulation of a Specific T-cell Line Require Processing of the Polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract);

199. Zisman, et al., "Dichotomy Between the T and the B Cell Epitopes of the Synthetic Polypeptide (T,G)-A-L", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract);

The subject application is a divisional of and claims the benefit under 35 U.S.C. §120 of U. S. Serial No. 09/885,227, filed June 20, 2001.

Accordingly, under 37 C.F.R. §1.98(d) copies of references 1-199 are not required to be provided to the United States Patent and Trademark Office because they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

Specifically, Items 1, 3, 4, 8-10, 12, 15-17, 19, 22, 23, 28, 29, 31, 36, 38-44, 47-65, 70, 71, 75-96, 98, 101, 102, 104-114, 116, 117, 121-124, 126-130, 134-136, 138, 141, 143-154, 156-159, 161-164, 166-186, 188, 192, 193, and 195-197 were disclosed in the October 18, 2002 Information Disclosure Statement, Items 2, 5-7, 11, 14, 18, 24-27, 32-35, 37, 45, 46, 66-69, 72-74, 97-100, 103, 115, 118-120, 125, 131-133, 137, 139, 140, 142, 160, 165, 187, 190, 191, 198, and 199 were disclosed in the October 18, 2002 Supplemental Information Disclosure Statement, and Items 20, 21, 30, 155, 189, and 194 were disclosed in the August 13, 2003 Second Supplemental Information Disclosure Statement, all filed in connection with U.S. Serial No. 09/885,227.

This Second Supplemental Information Disclosure Statement is being submitted before the issuance of a first Office Action on the merits in connection with the subject application. Accordingly, no fee is required and this Second Supplemental Information Disclosure Statement shall be considered pursuant to 37 C.F.R. §1.97(b)(3).

Applicants request that the Examiner review these publications and make them of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, is deemed necessary in connection with the filing of this Second Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



12/1/04
Date

John P. White
Reg. No. 28,678
Gary J. Gershik
Reg. No. 39,992

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	3 8 4 9 5 5 0	11/19/74	Teitelbaum et al.			
	US	3 9 9 1 2 1 0	11/09/76	Shea			
	US	4 3 3 9 4 3 1	7/13/82	Gaffer			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	8 8 1 0 1 2 0	12/29/88	PCT				
	WO	9 2 0 2 5 4 3	2/20/92	PCT				
	WO	9 4 0 3 4 8 4	2/17/94	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", J. Neurol. Sci., 1977, 31, 433-438;
		Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", Eur. J. Immunol., 1993, 23, 17-25;
		Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", Immunol. Letters, 1997, 58, 79-87;
		Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", Ann. Neurol., 1979, 6, 469-473;
		Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", Israel J. Med. Sci., 1972, 8, 1759-17
		Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", Neurol., 1978, 28, 336 (Abstract);
		Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in Progress in Multiple Sclerosis Research (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;
		Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis (Academic Press, New York, 1980) 105-107;
		Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", Immunological Rev., 1981, 55, 5-30;
		Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	5 2 0 4 0 9 9	4/20/93	Barbier et al.			
	US	5 5 5 4 3 7 2	9/10/96	Hunter et al.			
	US	5 5 8 3 0 3 1	12/10/96	Stern			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	9 4 2 6 7 7 4	11/24/94	PCT				
	WO	9 5 3 1 9 9 7	11/30/95	PCT				
	WO	9 5 3 3 4 7 5	12/14/95	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689;
		Arnon, et al., "On the Existence of Suppressor Cells", Int. Arch. Allergy Immunol., 1993, 100, 2-7;
		Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", Israel J. Med. Sci., 1993, 29, 175-181;
		Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", Therapeutic Immunol., 1994, 1, 65-70;
		Asakura and Rodriguez, "A Unique Population of Circulating Autoantibodies Promotes Central Nervous System Remyelination", Multiple Sclerosis, 1998, 4: 217-221;
		Asakura, et al., "Targeting of IgMκ Antibodies to Oligodendrocytes Promotes CNS Remyelination", J. Neurosci., 1998, 18(19): 7700-7708;
		Babu, et al., "Reevaluation of Response Patterns of Nonresponder Mice to GlPhe Polymers", Immunogen., 1983, 18(1): 97-100 (Abstract);
		Babu, et al., "Ir Gene Control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", J. Immunogenet., 1984, 11(3-4): 251-254;
		Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", Seminars in Neurol., June 1994, 14(2), 146-153;
		Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", Neurol., 1988, 38(Suppl. 2), 69-71;
		Baxevanis, et al., "Genetic Control of T-Cell Proliferative Responses to Poly ($Glu^{40}Ala^{60}$) and Poly ($Glu^{51}Lys^{34}Tyr^{15}$): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", Immunogenetics, 1980, 11: 617-628;
		Bieber, et al., "Antibody-Mediated Remyelination: Relevance to Multiple Sclerosis", Multiple Sclerosis, 2000, 6: S1-S5;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	5 6 2 3 0 5 2	04/22/97	McLean et al			
	US	5 6 2 7 2 0 6	05/06/97	Hupe et al			
	US	5 6 6 8 1 1 7	09/16/97	Shapiro			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	9 5 2 6 9 8 0	10/12/95	PCT				
	WO	9 5 3 1 9 9 0	11/30/95	PCT				
	WO	9 8 3 0 2 2 7	07/16/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bieber, et al., "Humoral Autoimmunity as a Mediator of CNS Repair", Trends in Neurosci., 2001, 24(11): S39-S44;
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Ann. Neurol., 1980, 8, 117 (Abstract);
		Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Trans. Am. Neurol. Assoc., 1980, 105, 348-350;
		Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", Ann. Neurol., 1982, 11, 317-319;
		Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", Ann. N.Y. Acad. Sci. (USA), 1984, 366-372;
		Bornstein, et al., "Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., Immunological and Clinical Aspects of Multiple Sclerosis (MTP Press, The Hague, 1984) 144-150;
		Bornstein, et al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", Neurol., 1985, 35 (Suppl. 1), 103 (Abstract);
		Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", Adv. Ther. (USA), 1987, 4, 206 (Abstract);
		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 408-414;
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", Neurol., 1988, 38(Suppl. 2), 66-69;
		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis, Roma (Italy), September 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	5 7 1 9 2 6 9	02/17/98	Acton, III et al.			
	US	5 7 3 4 0 2 3	03/31/98	Bishwajit et al.			
	US	5 8 5 8 9 6 4	01/12/99	Aharoni, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	0 0 0 5 2 4 9	02/03/00	PCT				
	WO	0 0 1 8 7 9 4	04/06/00	PCT				
	WO	0 0 2 0 0 1 0	04/13/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 408-414;
		Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", Neurol., 1988, 38(Suppl. 2), 66-69;
		Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from The International Multiple Sclerosis Conference: An Update on Multiple Sclerosis, Roma (Italy), September 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232;
		Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in Handbook of Multiple Sclerosis (S.D. Cook Marcel Rekker, ed., 1990) 469-480;
		Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", Neurol., 1991, 41, 533-539;
		Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in Treatment of Multiple Scleorsis: Trial Design, Results and Future Perspectives (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198;
		Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", J. Neuropath. Exp. Neurol., 1983, 42, 356 (Abstract);
		Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", Ann. N.Y. Acad. Sci. (USA), 1984, 436, 498-499;
		Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", Neurol., 1985, 35, 1754-1759;
		Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", Neurol., 1985, 35 (Suppl. 1), 170 (Abstract);

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	5 8 8 6 1 5 6	03/23/99	McLean et al.			
	US	5 9 5 8 9 7 2	09/28/99	Hupe, et al.			
	US	6 2 1 4 7 9 1	04/10/01	Arnon, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	0 0 2 7 4 1 7	05/18/00	PCT				
	WO	0 1 8 5 7 9 7	11/15/01	PCT				
	WO	0 1 5 2 8 7 8	07/26/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", Neurol., 1986, 36, 92-94;
		Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", Neurol., 1991, 41, 1317-1319;
		Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", Drug Therapy, 1990, 31-32, 37-39, 42-43;
		Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991;
		Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993;
		Cohen, "Fundamental Immunology", Systemic Autoimmunity, 4th Ed., 1999, 1083;
		Cotton, "Options for Multiple Sclerosis Therapy", J.A.M.A. Medical News & Perspectives, 1994, 272(18), 1393;
		De Kruyff, et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", Eur. J. Immunol., 1987, 17 (8): 1115-1120 (Abstract);
		Deeb, et al., "Comparision of Freund's and Ribi Adjuvants for Inducing Antibodies to the Synthetic Antigen (TG)-AL in Rabbits", J. Immunol. Methods, 1992, 152(1): 105-113 (Abstract);
		Dorling, et al., "Prospects for Xenografting", Curr. Opinions Immunol., 1994, 6, 765-769;
		Durelli, "Immunotherapeutics of Multiple Sclerosis", Instituto di Clinica delle Malattie del Sistema Nervoso Universita di Torino, 467-475;
		Falo et al., "Analysis of Antigen Presentation by Metabolically Inactive Accessory Cells and Their Isolated Membranes", Proc. Natl. Acad. Sci. USA, 1985, 82(19): 6647-6651 (Abstract);

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	6 3 4 2 4 7 6	01/29/02	Konfino et al.			
	US	6 3 6 2 1 6 1	03/26/02	Konfino et al.			
	US-2001	00 5 5 5 6 8 A1	12/27/01	Gilbert et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	0 1 9 3 8 9 3	12/13/01	PCT				
	WO	0 1 6 0 3 9 2	08/23/01	PCT				
	WO	0 1 9 3 8 2 8	12/13/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ferrara, et al., "Graft-Versus-Host Disease", New Eng. J. Med., 1991, 324, 667-674;
		Francis, "The Current Therapy of Multiple Sclerosis", J. Clin. Pharmacy and Therapeutics, 1993, 18, 77-84;
		Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", Department of Chemical Immunology, The Weizmann Institute of Science, 1994;
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, 1994;
		Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Israeli Biochem. Soc., 1994, 21-22 (Abstract);
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", Israeli Immunol. Soc., May 3-4, 1994 (Abstract);
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen- Presenting Cells", J. Neurochem., 1994, 63(Suppl. I), 561;
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits theBinding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Neurochem Mtg., August 14-19, 1994;
		Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236;
		Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", J. Immunol., 1998, 160, 4386-4397;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US-2002	00 3 7 8 4 8 A1	03/28/02	Eisenbach-Schwartz et al.			
	US-2002	00 3 7 8 4 8 A1	03/28/02	Eisenbach-Schwartz et al.			
	US-2003	00 0 4 0 9 9 A1	01/02.03	Eisenbach-Schwartz et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	WO	0 1 9 7 8 4 6	12/27/01	PCT				
	EP	0 3 5 9 7 8 3	08/22/90	Europe				
	EP	0 3 8 3 6 2 0	11/29/95	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-reactive T Cell Clones", Proc. Natl. Acad. Sci., October 1998, 95, 12528-12531;
		Fridkis-Hareli, et al., "Binding of Random Copolymers of Three Amino Acids to Class II MHC Molecules", Intl. Immunol., 1999, 11(5): 635-641;
		Fridkis-Hareli, et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, Human Immunology, 2000, 61(7), 640-650 (Abstract);
		Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the Macrophage Procoagulant Activity Assay", Int. Immunol., 1990, 2(8), 713-718;
		Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", Current Opin. Immunol., 2000, 12 (6): 704-711;
		Henry, Celia M., "Special Delivery", Chem. and Eng. News, Sept. 18, 2000, 49-54;
		Herzenberger, et al., "Lack of Immune Response Gene Control for Induction of Epitope-specific Suppression by TGAL Antigen", Nature, 1982, 295: 329-331 (Abstract);
		Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", Neurol., 1994, 7, 250-254;
		Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in Congress for Advances in the Understanding and Treatment of Multiple Sclerosis, Boston (USA), Oct. 28-29, 1992;
		Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", Ann. Neurol., 1994, 36(Suppl.), 115-117;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	09 3 5 9 0 9 9	07/12/99	Strominger et al.			
	US	09 4 0 5 7 4 3	09/24/99	Gad et al.			
	US	09 4 8 7 7 9 3	01/20/00	Eisenbach-Schwartz, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", Chemical Abstracts, 1996, 125, 291993b;
		Ju, et al., "Idiotypic Analysis of Antibodies Against the Terpolymer L-glutamic Acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT Idiotype Following Immunization with Various Synthetic Polymers Containing Glutamic Acid and Tyrosine", Eur. J. Immunol., 1979, 9(7): 553-560 (Abstract);
		Kay, et al., "The Mechanism of Action of FK 506", Transplantation Proceedings, 1990, 22(1, Suppl. 1), 96-99;
		Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Guinea Pigs" J. Neurol. Sci., 1979, 42, 267-274;
		Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", Int. Arch. Allergy Immunol., 1993, 102, 309-320;
		Kepsutlu, et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3), 227-235 (Abstract);
		Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", Israel Neurological Assoc., December 19-20, 1994, Herzliya (Israel), 17;
		Kropshofer, et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH_2-Terminal Including Proline as a Stop Signal for Trimming", J. Immunol., 1993, 151: 4732-4742;
		Lai, et al., "Complementation of Class II a Alleles in the Immune Response to (Glulystyr) Polymers", Exp. Clin. Immunogenet., 1986, 3(1): 38-48 (Abstract);
		Lai, et al., "Monoclonal T Cell Responses to Two Epitopes on a Single Immunogen Controlled by Two Distinct Genes", J. Immunol., 1986, 136(10): 3799-3804 (Abstract);

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	09 6 2 0 2 1 6	07/20/00	Eisenbach-Schwartz, et al.			
	US	09 7 6 5 3 0 1	01/22/01	Eisenbach-Schwartz, et al.			
	US	09 7 6 5 6 4 4	1/22/01	Eisenbach-Schwartz, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", Israel J. Med. Sci., 1979, 15, 868-869 (Abstract);
		Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", J. Immunol., 1979, 123, 2156-2160 (Abstract);
		Lee, et al., "Peptide and Protein Drug Delivery" in Advances in Parenteral Sciences (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695;
		Li et al., "Glatiramer Acetate Blocks the Activation of THP-1 Cells by Interferon-γ", Eur. J. Pharmacol., 1998, 342: 303-310;
		Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", J. Neurol. Sci., 1983, 62, 281-293;
		Matsunaga, et al., "Complementation of Class II A Alleles in the Immune Response to (Glu-Lys-Tyr) Polymers", Yokohama Med. Bull., 1988, 39(1-2): 9-19 (Abstract);
		Maurer, et al., "Interpretations of Immune Responses of Mice to Poly(Glu60Lys40), its Modified Derivatives, and the Terpolymers Poly (Glu55Lys37Leu8) and Poly (Glu56Lys37Ser7)", Clin. Immunol. Immunopathol., 1980, 15(3): 344-356 (Abstract);
		McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", J. Neurol. Sci., 1980, 46, 137-143;
		McGavern, et al., "Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis", The Neuroscientist, 1999, 5(1): 19-28;
		Meiner, "COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple-Sclerosis: One Year Follow-up", J. Neurol., 1991(Suppl. 1) (Abstract);
		Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis – Two-year Follow-up", in 9th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Florence (Italy), October-November, 1993, 48 (Abstract);
		Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in Encycl. Molecular Bio. (Oxford Blackwell Science Ltd, 1994) 602-606;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US	09 7 6 8 8 7 2	01/23/01	Aharoni et al.			
	US	09 8 1 6 9 8 9	03/23/01	Gad et al.			
	US	09 8 7 5 4 2 9	06/05/01	Yong et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", Israel J. Med. Sci., 1992, 28, 486 (Abstract);
		Milo, et al., "Copolymer-1 (COP-1) Regulates Class II MHC Expression and Cytokine Synthesis in the THP-1 Monocyte-Macrophage Cell Line" in The IBC Conference on Multiple Sclerosis, San Diego (USA), December 10, 1993 (Abstract);
		Milo, et al., "Additive Effect of Copolymer-1 and Interferon-β on the Immune Response to Myelin Basic Protein", Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine, 1994, 22;
		Milo, et al., "Copolymer-1 and Interferon-β Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", J. Neuroimmunol., 1994, 54, 183 (Abstract);
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", Neurol., 1994, 44(Suppl. 2), A212;
		Milo, et al., "Additive Effects of Copolymer-1 and Interferon β-1b on the Immune Response to Myelin Basic Protein", J. Neuroimmunol., 1995, 61, 185-193;
		Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", Neurol., 1994, 44(Suppl. 2), A212;
		Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", Neurologic Clinics, 1990, 8(1), 119-141;
		Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", Am. Family Physician, 1994, 50(4), 845-847;
		O'Connor, et al., "Powders" in The Science and Practice of Pharmacy, Remington, 1995, 2, 1598-1614 Pender et al. Int. Med. Journal, 2002, 32: 554-563;
		Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Prat, et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy," Ann. Neurol., 1999, 46: 253-256;
		Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84;
		Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington, 1995, 2, 1380-1416;
		Rodriguez, Neurological Therapeutics, 1998, 15(3): 245-250;
		Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396;
		Schlegel,et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810;
		Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc. Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1-5, 1995, 224a (Abstract);
		Schwartz, et al., "Gene Complementation in the T Lymphocyte Proliferative Response to Poly (Glu57Lys38Tyr5): Evidence for Effects of Polymer Handling and Gene Dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract);
		Sela, et al., "Experimental Allergic Encephalomyelitis" in Menarini Series on Immunopathology, vol. 1, First Symposium of Organ Specific Autoimmunity", Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Basel, 1978), 9-21;
		Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", Makromol. Chem. Macromol. Symp., 1993, 70/71, 147-155;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5;
		Sykes, "Immunobiology of Transplantation", Faseb J., 1996, 10, 721-730;
		Tarcic, et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract);
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", Israel J. Med. Sci., 1971, 7, 630-631 (Abstract);
		Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", Nature, 1972, 240, 564-566;
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", Clin. Immunol. Immunopath., 1974, 3, 256-262;
		Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", Israel J. Med. Sci., 1974, 10(9), 1172-1173;
		Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", Israel J. Med. Sci., 1977, 13, 1038 (Abstract);
		Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in Cell Biology and Immunology of Leukocyte Function (Academic Press, New York, 1979) 681-685;
		Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer – Relevance to Multiple Sclerosis", in Humoral Immunity in Neurological Diseases (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613;
		Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in Proc. 7th Eur. Immunol. Mtg., Jerusalem, September 8-13, 1985 (Abstract);
		Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", Proc. Natl. Acad. Sci. USA, 1988, 85, 9724-9728;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" J. Israel Med. Assoc., 1989, CXVI(9), 453-456;
		Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137-141;
		Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", Neurol., 1994, 44(Suppl. 2), A358;
		Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", Israel J. Med. Sci., 1997, 33, 280-284;
		The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", Abstracts of Symposia and Free Communication, Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6;
		Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", Immunol. Today, 1985, 6(4), 141;
		Tisch, et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 437-438;
		Trannoy, et al., "Epitope-specific Regulation of the T Cell Repertoire: Carrier Recognition in Association with I-E or I-A Does Not Influence the Restriction of Hapten-Specific T Cells", Eur. J. Immunol., 1985, 15(12): 1215-1221 (Abstract);
		Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", Transplantation, 1991, 52, 15-20;
		Van Noort, et al., International Review of Cytology, 1995, 178: 127-205;
		Warrington, et al., "Human Monoclonal Antibodies Reactive to Oligodendrocytes Promote Remyelination in a Model of Multiple Sclerosis", Neurobiology, 2000, 97(12): 6820-6825;
		Warrington, et al., "Immunoglobulin-Mediated CNS Repair", J. Allergy Clin. Immunol., 2001, S121-S125;
		Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", Israel J. Med. Sci., 1972, 8, 656-657

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 60726-AZ	U.S. Serial No. 10/776,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant: Moses Rodriguez and Daren Ure	
	Filing Date: February 10, 2004	Group Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Webb, et al., "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", Immunochem., 1976, 13, 333-337;
		Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984, 933;
		Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", Current Opinion in Neurol. and Neurosurgery, 1992, 5, 203-211;
		Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (letter)" Neur. Neurochir. Pol., 1990, 24, 113;
		Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444;
		Zisman, et al., "Direct Binding of a Synthetic Multichain Polypeptide to Class II Major Histocompatibility Complex Molecules on Antigen-presenting Cells and Stimulation of a Specific T-cell Line Require Processing of the Polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract);
		Zisman, et al., "Dichotomy Between the T and the B Cell Epitopes of the Synthetic Polypeptide (T,G)-A-L", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract);

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant